Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston makes hostile bid for Guidant but Johnson & Johnson won't rise to the bait

This article was originally published in Clinica

Executive Summary

In what has been described by analysts as a "gutsy" move, Boston Scientific this week attempted to upstage one of the biggest healthcare giants by moving in on its acquisition target, writes Tina Tan. The Natick, Massachusetts-based medical device firm offered to buy Guidant for a consideration of $25bn, some $3.5bn more than Johnson & Johnson's revised offer for the cardiology company, announced last month.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT058117

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel